Arbutus Biopharma stock analysis
Arbutus Biopharma (0SGC) Share Price & Analysis
0SGC Stock Chart & Stats
- Day’s Range
- $3.32 - $3.32
- 52-Week Range
- $3.32 - $3.32
- Previous Close
- $3.32
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $619.30M
- Enterprise Value
- $620.04M
- Total Cash (Recent Filing)
- $337.49M
- Total Debt (Recent Filing)
- $328.00K
- Price to Earnings (P/E)
- 3.6
- Beta
- 1.25
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- -0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Profitability And Cash Generation
The latest period shows a substantial shift to profitability, with very high margins and strong operating and free cash flow. If this improvement persists, it could provide substantial internal funding for clinical development, reduce financing dependence, and strengthen strategic flexibility over the next several quarters.
Low Financial Leverage
Minimal debt gives Arbutus considerable financial flexibility relative to a more heavily leveraged biotechnology company. The balance sheet can support continued research investment and help the company withstand development uncertainty without the same interest burden or refinancing pressure associated with substantial borrowing.
HBV Pipeline Progress
The reported clinical activity strengthens the strategic case for Arbutus’s HBV platform, particularly because current treatment options are often lifelong and non-curative. Durable suppression and functional cure signals could support further development, partnering interest, and differentiation if confirmed in later studies.
Bears Say
Declining And Volatile Revenue
A falling latest-period revenue base makes the current earnings step-change harder to assess as a durable operating trend. Volatile revenue can complicate planning and reduce confidence in recurring funding capacity, especially while the company continues advancing clinical programs that require sustained investment.
Inconsistent Cash Flow History
The contrast between recent cash generation and several years of cash burn indicates that the latest result has not yet established a reliable pattern. If historical volatility returns, Arbutus may need to conserve resources, raise external capital, or reduce development flexibility to fund its pipeline.
Limited Recurring Product Revenue
Arbutus does not yet have a broadly commercialized product base producing recurring operating revenue, leaving financial performance dependent on collaborations, licensing payments, investment income, and external financing. This increases the importance of successful development and commercialization milestones for long-term self-funding.
Arbutus Biopharma News
0SGC FAQ
What was Arbutus Biopharma’s price range in the past 12 months?
What is Arbutus Biopharma’s market cap?
When is Arbutus Biopharma’s upcoming earnings report date?
How were Arbutus Biopharma’s earnings last quarter?
Is Arbutus Biopharma overvalued?
Does Arbutus Biopharma pay dividends?
What is Arbutus Biopharma’s EPS estimate?
How many shares outstanding does Arbutus Biopharma have?
What happened to Arbutus Biopharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Arbutus Biopharma?
What is the TipRanks Smart Score and how is it calculated?
Arbutus Biopharma Stock Smart Score
Company Description
Arbutus Biopharma
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lindsay Androski
- Employees
- 19
- Website
- www.arbutusbio.com
- Address
- 701 Veterans Circle, Warminster, PA, 18974, US
Arbutus Biopharma (0SGC) Earnings & Revenues
0SGC Earnings Call
Earnings Call SentimentPositive
The earnings call reflects a positive outlook with strong financial positioning and promising clinical trial data for HBV treatments. However, ongoing legal challenges and high operational cash burn present concerns.
View all GB:0SGC earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 6 |
| Technical Analysis | 0 | 1 | 0 |
| Moving Averages | 4 | 2 | 6 |










